[Mass-screening for ovarian cancer by transvaginal ultrasonography--study on tumor markers at the second screening]

Examination of tumor markers (CAMPAS) at the second screening in our mass-screening for ovarian cancer was evaluated. CAMPAS has been performed in 866 women with enlarged ovaries over 30mm in size among 20,242 who received the first screening by transvaginal ultrasonography. In those with semi-malignant and malignant ovarian tumor (ovarian cancer), their serum levels of CA125, CEA, CA19-9, AFP and L-LDH were also measured (Combination Assay) and CA125, CEA, CA19-9, AFP, CA602, CA54 and CA61 antigens in removed tumor tissues were studied by immunoperoxidase staining (Tumor Assay). The results were as follows: 1) Ten of the 866 women were positive for CAMPAS, however, only one of them was found to have ovarian cancer. 2) Of the 20,242 women, six were found to have ovarian cancer: all in stage I and all detected among these 866 women. 3) Of the 6 women with ovarian cancer, three had high serum levels in the Combination Assay, and 4 had positive finding in the Tumor Assay, but of the 4 women with a positive Tumor Assay, one had different kinds of tumor markers in serum and one did not have a high serum level. Thus, CAMPAS was not useful as the second screening method in our mass-screening system for ovarian cancer.